Abstract:Neuropsychiatric disorders affect millions of people globally. Despite their high prevalence, the precise molecular mechanisms behind these conditions remain largely unclear. A complex interplay of genetic, developmental, and environmental factors may increase susceptibility to these disorders, with specific molecular changes potentially influencing disease onset and progression. Understanding these molecular pathways is crucial for deepening our knowledge of neuropsychiatric pathophysiology and for developing targeted therapies. The Research Topic Molecular Mechanisms of Neuropsychiatric Diseases is the second volume and the continuation of the first volume [1], being created in response to the high interest and positive reception it received in the first volume.This research collection aims to uncover key molecular mechanisms in neuropsychiatric disorders and explore how they might inform therapeutic strategies. The progress in understanding these disorders has been slowed by a lack of clear anatomical and molecular mechanism understanding.The papers in this collection address these obstacles by connecting signs and symptoms to underlying anatomical and molecular alterations.The review by Azevedo et al examines how the activation of the sympathoadrenal medullary system and the hypothalamic-pituitary-adrenal axis in response to stress impacts memory formation, particularly in fear and traumatic memories linked to post-traumatic stress disorder (PTSD).Catecholamines like norepinephrine (NE) and epinephrine (EPI) play key roles in adaptive responses to stress and are involved in contextual fear memory enhancement through β2-adrenoceptor (β2-AR) activation [2], influencing the brain via the vagus nerve and blood glucose changes [3,4]. This review highlights that EPI is particularly influential in fear memories, activating the hippocampal Nr4a2 mRNA expression related to cAMP response element-binding protein (CREB), which plays a significant role in contextual fear memory consolidation under stressful conditions [5]. An imbalance in this system, especially over-active sympathetic responses, contributes to the persistence of traumatic memories in PTSD, with some patients [6] and animal PTSD models showing elevated catecholamine levels [7]. The authors suggest that treatments such as sotalol, a β-AR blocker [8], and nepicastat, a dopamine β-hydroxylase inhibitor [9], could reduce PTSD risk by preventing the consolidation of traumatic memories. These drugs appear to regulate gene expression in the hippocampus (Nr4a, Npas4 or Bdnf), potentially fostering more neutral contextual memories [8,9]. These treatment approaches, combined with therapy, may help PTSD patients build resilience and cope with trauma by down-regulating excessive catecholamine effects and dysregulated gene activity.A brief research report article by Bartsch et al investigates how traumatic stress leads to persistent neural changes, focusing on synaptic plasticity in a pathway between the neurons of the posterior ventral segment of the medial amygdala and the ventrolateral segment of the ventromedial hypothalamus. Using the mGRASP imaging technique, researchers observed an increase in synapse formation in this pathway in mice exposed to acute stress compared to controls. Chemogenetic inhibition of CaMKIIα-expressing neurons in the medial amygdala during stress reduced these synaptic changes, suggesting excitatory activity drives this plasticity. Additionally, blocking NMDA receptors prevented stress-induced synapse formation, highlighting an NMDA receptor-dependent mechanism. These structural changes in the medial amygdala and the ventromedial hypothalamus pathway may underlie lasting behavioural effects of traumatic stress, such as those seen in PTSD and social behaviour changes, shedding light on potential targets for intervention.affects stress responses, highlighting the role of dopaminergic neurotransmission in stress susceptibility and resilience. Researchers compared wild-type (WT) and DAT-knockout (KO) mice under chronic stress, observing that DAT-KO mice showed resistance to stress-related anxiety behaviours. These findings suggest that loss of DAT may protect against stress-induced anxiety-like behaviours, underscoring the significance of dopamine pathways in stress resilience.gene, which encodes a subunit of the GABAB receptor (GABABR) critical for inhibitory neurotransmission in the brain, impact receptor structure and function. A 7-year-old boy with Level 3 Autism Spectrum Disorder was found to carry a de novo GABBR2 p.Arg212Gln variant, identified as a variant of unknown significance via whole exome sequencing. Although treatment with the GABABR agonist baclofen showed no improvement, researchers investigated whether this variant might contribute to patient`s symptoms. Using molecular dynamics simulations and in vitro experiments, they studied how the p.Arg212Gln variant, along with -Abstract Truncated-

Behavioral and Transcriptomic Changes Following Brain-Specific Loss of Noradrenergic Transmission

Corticolimbic Transcriptome Changes are State-Dependent and Region-Specific in a Rodent Model of Depression and of Antidepressant Reversal

Inhibition of norepinephrine signaling during a sensitive period disrupts locus coeruleus circuitry and emotional behaviors in adulthood

Deletion of Murine Astrocytic Vesicular Nucleotide Transporter Increases Anxiety and Depressive-Like Behavior and Attenuates Motivation for Reward

Norepinephrine alters the expression of genes involved in neuronal sprouting and differentiation: relevance for major depression and antidepressant mechanisms

Noradrenergic modulation of basolateral amygdala neuronal activity: opposing influences of alpha-2 and beta receptor activation

Vesicular monoamine transporter 2 mediates fear behavior in mice

Transgenic mice lacking CREB and CREM in noradrenergic and serotonergic neurons respond differently to common antidepressants on tail suspension test

Sex linked behavioral and hippocampal transcriptomic changes in mice with cell-type specific Egr1 loss

Editorial: Molecular mechanisms of neuropsychiatric diseases, volume II

The Role of Vesicular Glutamate Transporter Type 3 in Social Behavior, with a Focus on the Median Raphe Region

Frontal cortex norepinephrine, serotonin, and dopamine dynamics in an innate fear-reward behavioral model

Neurexin1α knockout rats display oscillatory abnormalities and sensory processing deficits back-translating key endophenotypes of psychiatric disorders

Understanding the neural code of stress to control anhedonia

Lesions of the Dorsal Noradrenergic Bundle Simultaneously Enhance and Reduce Responsivity to Novelty in a Food Preference Test

NMDARs Drive the Expression of Neuropsychiatric Disorder Risk Genes Within GABAergic Interneuron Subtypes in the Juvenile Brain

RNA-seq Co-Expression Network Analysis Reveals Anxiolytic Behavior of Mice with Efnb2 Knockout in Parvalbumin+ Neurons

Deleting Snord115 genes in mice remodels monoaminergic systems activity in the brain toward cortico-subcortical imbalances

Noradrenergic Function in Depressive Disorders

Midbrain projection to the basolateral amygdala encodes anxiety-like but not depression-like behaviors

Differentially Expressed Genes of the Slc6a Family as Markers of Altered Brain Neurotransmitter System Function in Pathological States in Mice